Sugi Predict

Sugi Predict / Compounds / SCHEMBL1410127

SCHEMBL1410127

SCHEMBL1410127

N[C@@H](CCC(=O)OC(=O)C[C@H](N)C(=O)OC(=O)CC[C@H](N)C(=O)O)C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC1A1 P43005 2/20 0.48
▸ GSR P00390 2/20 0.48
▸ GRIK1 P39086 2/20 0.48
▸ GRIK2 Q13002 2/20 0.48
▸ GRM8 O00222 2/20 0.48
▸ GRM6 O15303 2/20 0.48
▸ GRM7 Q14831 2/20 0.48
▸ GRM4 Q14833 2/20 0.48
▸ GRIN2D O15399 1/20 0.48
▸ GRIN3B O60391 1/20 0.48
▸ CYP1A2 P05177 1/20 0.48
▸ GRM5 P41594 1/20 0.48
▸ GRIA1 P42261 1/20 0.48
▸ GRIA2 P42262 1/20 0.48
▸ GRIA3 P42263 1/20 0.48
▸ SLC1A3 P43003 1/20 0.48
▸ SLC1A2 P43004 1/20 0.48
▸ GRIA4 P48058 1/20 0.48
▸ GRIN1 Q05586 1/20 0.48
▸ GRIN2A Q12879 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17184332 0.97 SLC1A1 (0.46) SLC1A1GSRGRIK1GRIK2GRM8
SCHEMBL693114 0.93 GRIK1 (0.44) SLC1A1GSRGRIK1GRIK2GRM8
SCHEMBL9817851 0.93 GRIK1 (0.44) SLC1A1GSRGRIK1GRIK2GRM8
SCHEMBL11493168 0.92 GSR (0.42) SLC1A1GSRGRIK1GRIK2GRM8
SCHEMBL27574890 0.91 SLC1A1 (0.42) SLC1A1GSRGRIK1GRIK2GRM8
SCHEMBL2994699 0.91 SLC1A1 (0.54) SLC1A1GSRGRIK1GRIK2GRM8
SCHEMBL3430330 0.91 SLC1A1 (0.54) SLC1A1GSRGRIK1GRIK2GRM8
SCHEMBL7717181 0.91 SLC1A1 (0.54) SLC1A1GSRGRIK1GRIK2GRM8
SCHEMBL931954 0.91 SLC1A1 (0.54) SLC1A1GSRGRIK1GRIK2GRM8
SCHEMBL6267781 0.91 SLC1A1 (0.54) SLC1A1GSRGRIK1GRIK2GRM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 499 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190160188-A1 Radiolabeled Alpha-Melanocyte Stimulating Hormone Hybrid Peptide for Melanoma Targeting STC UNM (US) 2019-05-30 — — US claimed
US-20190153113-A1 CD39 VASCULAR ISOFORM TARGETING AGENTS INNATE PHARMA (FR) 2019-05-23 — — US claimed
CN-103768118-B Bite by mosquitos itch-relieving and sterilizing liquid and preparation method thereof BAOJI MEILIN BIOLOGICAL SCIENCE & TECHNOLOGY DEVELOPMENT CO., LTD. (CN) 2016-05-11 — — CN claimed
CN-103768118-A Disinfectant for reliving itching due to mosquito bite and preparation method thereof BAOJI MEILIN BIOLOG SCIENCE & TECHNOLOGY DEV CO LTD 2014-05-07 — — CN claimed
CN-101721720-A Nitroimidazole-amino acid compound nuclide hypoxic contrast agent and precursor thereof JIANPING RUAN 2010-06-09 — — CN claimed
WO-2007053943-A1 THE USE OF COMPOSITIONS COMPRISING KETOACIDS AND AMINO ACIDS FOR INCREASING MUSCLE MASS AND MUSCLE PERFORMANCE MULTI FORMULATIONS LTD. (CA) 2007-05-18 — — WO claimed
US-20070105942-A1 Supplemental dietary composition for turning on anabolic switches in muscle, stimulating and/or optimizing protein synthesis, and/or potently signaling muscle building and/or growth via molecular pathways MULTI FORMULATIONS LTD. (CA) 2007-05-10 — — US claimed
EP-0548228-A1 LIPASE VARIANTS NOVO NORDISK A/S (DK) 1993-06-30 — — EP claimed
WO-1992005249-A1 LIPASE VARIANTS NOVO NORDISK A/S (DK) 1992-04-02 — — WO claimed
CN-117903324-B Pharmaceutical preparation for targeted degradation of hepatitis B virus X protein and application thereof 珠海市人民医院 2024-07-23 — — CN disclosed
CN-117903324-A Pharmaceutical preparation for targeted degradation of hepatitis B virus X protein and application thereof 珠海市人民医院 2024-04-19 — — CN disclosed
WO-2024074847-A1 COMPOSITIONS FOR DETECTING BIOLOGICAL AGENTS PATH SPRAY LTD (GB) 2024-04-11 — — WO disclosed
WO-2024069191-A1 CLOSTRIDIAL NEUROTOXIN FOR USE IN A TREATMENT OF BLADDER PAIN SYNDROME IPSEN BIOPHARM LIMITED (GB) 2024-04-04 — — WO disclosed
WO-2024069176-A1 CLOSTRIDIAL NEUROTOXINS COMPRISING AN ACTIVATING EXOGENOUS PROTEASE CLEAVAGE SITE IPSEN BIOPHARM LIMITED (GB) 2024-04-04 — — WO disclosed
EP-0723456-A1 METHODS FOR STIMULATING ERYTHROPOIESIS USING THROMBOPOIETIN THE UNIVERSITY OF WASHINGTON (US) 1996-07-31 — — EP disclosed
WO-1996020955-A1 PURIFIED THROMBOPOIETIN AND METHOD OF MAKING IT ZYMOGENETICS, INC. (US) 1996-07-11 — — WO disclosed
WO-1996017062-A1 LOW MOLECULAR WEIGHT THROMBOPOIETIN ZYMOGENETICS, INC. (US) 1996-06-06 — — WO disclosed
WO-1996017067-A1 METHOD FOR SECRETING THROMBOPOIETIN POLYPEPTIDES ZYMOGENETICS, INC. (US) 1996-06-06 — — WO disclosed
WO-1995021920-A1 HEMATOPOIETIC PROTEIN AND MATERIALS AND METHODS FOR MAKING IT ZYMOGENETICS, INC. (US) 1995-08-17 — — WO disclosed
WO-1995021626-A1 METHODS FOR STIMULATING ERYTHROPOIESIS USING THROMBOPOIETIN UNIVERSITY OF WASHINGTON (US) 1995-08-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190160188-A1 Radiolabeled Alpha-Melanocyte Stimulating Hormone Hybrid Peptide for Melanoma Targeting MC1R, MC3R, MC4R SLC1A1 798/4885GSR 4091/4885GRIK1 4610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.